dc.contributor.author |
Nelde, Annika |
|
dc.contributor.author |
Backert, Linus |
|
dc.contributor.author |
Schuster, Heiko |
|
dc.contributor.author |
Werner, Jan-Ole |
|
dc.contributor.author |
Klein, Reinhild |
|
dc.contributor.author |
Kohlbacher, Oliver |
|
dc.contributor.author |
Kanz, Lothar |
|
dc.contributor.author |
Rammensee, Hans-Georg |
|
dc.contributor.author |
Stevanović, Stefan |
|
dc.contributor.author |
Kowalewski, Daniel Johannes |
|
dc.contributor.author |
Salih, Helmut R. |
|
dc.contributor.author |
Walz, Juliane S. |
|
dc.date.accessioned |
2020-02-03T09:50:32Z |
|
dc.date.available |
2020-02-03T09:50:32Z |
|
dc.date.issued |
2018 |
|
dc.identifier.issn |
2162-402X |
|
dc.identifier.uri |
http://hdl.handle.net/10900/97546 |
|
dc.language.iso |
en |
de_DE |
dc.publisher |
Taylor & Francis Inc |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1080/2162402X.2017.1316438 |
de_DE |
dc.subject.ddc |
570 |
de_DE |
dc.subject.ddc |
610 |
de_DE |
dc.title |
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20190321153956_04402 |
|
utue.personen.roh |
Nelde, Annika |
|
utue.personen.roh |
Kowalewski, Daniel J. |
|
utue.personen.roh |
Backert, Linus |
|
utue.personen.roh |
Schuster, Heiko |
|
utue.personen.roh |
Werner, Jan-Ole |
|
utue.personen.roh |
Klein, Reinhild |
|
utue.personen.roh |
Kohlbacher, Oliver |
|
utue.personen.roh |
Kanz, Lothar |
|
utue.personen.roh |
Salih, Helmut R. |
|
utue.personen.roh |
Rammensee, Hans-Georg |
|
utue.personen.roh |
Stevanovic, Stefan |
|
utue.personen.roh |
Walz, Juliane S. |
|
dcterms.isPartOf.ZSTitelID |
Oncoimmunology |
de_DE |
dcterms.isPartOf.ZS-Issue |
Article e1316438 |
de_DE |
dcterms.isPartOf.ZS-Volume |
7 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |
utue.fakultaet |
07 Mathematisch-Naturwissenschaftliche Fakultät |
de_DE |